Progress research on immune checkpoint inhibitors for advanced biliary tract cancer treatment
10.12354/j.issn.1000-8179.2023.20230982
- VernacularTitle:晚期胆道癌免疫检查点抑制剂治疗的研究进展
- Author:
Jiaman MA
1
;
Yu YANG
Author Information
1. 四川大学华西医院腹部肿瘤科(成都市 610000)
- Keywords:
biliary tract cancer(BTC);
immunotherapy;
immune checkpoint inhibitors(ICIs);
combination therapy
- From:
Chinese Journal of Clinical Oncology
2023;50(22):1168-1173
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancers(BTCs),encompassing gallbladder cancer and intra-and extra-hepatic cholangiocarcinoma,primarily manifest as highly invasive adenocarcinomas with a notably poor prognosis.BTCs typically initiate insidiously,and even surgically resectable patients confront a heightened risk of recurrence,with postoperative adjuvant chemotherapy offering limited survival benefits.For unresectable or metastatic BTCs,systemic antitumor drug therapy remains the primary treatment.Recently,significant progress has been made in the treat-ment of advanced BTCs with the emergence of immune checkpoint inhibitors(ICIs)and molecularly targeted drugs alongside traditional chemotherapy.This progress has substantially broadened clinical treatment options and improved patient prognoses.Combining first-line chemotherapy with immunotherapy has emerged as a favorable treatment strategy over conventional chemotherapy.Additionally,the com-bination of chemotherapy with immunotherapy,anti-angiogenic targeted therapy,dual immunotherapy,or dual immunotherapy has exhib-ited promising outcomes.Explorations into second-line immunotherapy have also been actively explored.This article provides an overview of the current status and recent advances in immunotherapy for advanced BTCs.
